BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

14329

532815

SMSPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SMS PHARMACEUTICALS LTD. performance

Today’s low

Today’s high

₹ 233.00 ₹ 240.24
₹ 235.69

52 week low

52 week high

₹ 175.25 ₹ 398.00
₹ 235.69

Open Price

₹ 240.24

Prev. Close

₹ 240.24

Volume (Shares)

79685.00

Total traded value

₹ 187.80

Upper Circuit

₹ 288.28

Lower Circuit

₹ 192.19

info

SMS PHARMACEUTICALS LTD. Share Price Update

As of the latest trading session, SMS PHARMACEUTICALS LTD. share price is currently at ₹ 235.69, which is down by ₹ -4.55 from its previous closing. Today, the stock has fluctuated between ₹ 233.00 and ₹ 240.24. Over the past year, SMS PHARMACEUTICALS LTD. has achieved a return of 15.69 %. In the last month alone, the return has been 9.56 %. Read More...

SMS PHARMACEUTICALS LTD. fundamentals


  • Market cap (Cr)

    1,995.16

  • P/E Ratio (TTM)

    33.50

  • Beta

    1.15

  • Book Value / share

    73.15

  • Return on equity

    9.28%

  • EPS (TTM)

    7.18

  • Dividend yield

    0.16%

  • Net profit/quarter (Cr)

    17.17

info icon alternate text
  • Market cap (Cr)

    1,982.97

  • P/E Ratio (TTM)

    32.75

  • Beta

    1.06

  • Book Value / share

    73.15

  • Return on equity

    9.28%

  • EPS (TTM)

    7.18

  • Dividend yield

    0.16%

  • Net profit/quarter (Cr)

    17.17

info icon alternate text

SMS PHARMACEUTICALS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 173.35
Operating Expense 152.95
Net Profit 17.17
Net Profit Margin (%) 9.90
Earnings Per Share (EPS) 2.03
EBITDA 35.43
Effective Tax Rate (%) 23.79
Particulars SEP 2024 (Values in Cr)
Revenue 196.75
Operating Expense 178.12
Net Profit 14.26
Net Profit Margin (%) 7.24
Earnings Per Share (EPS) 1.68
EBITDA 33.17
Effective Tax Rate (%) 28.48
Particulars JUN 2024 (Values in Cr)
Revenue 164.45
Operating Expense 144.04
Net Profit 16.33
Net Profit Margin (%) 9.93
Earnings Per Share (EPS) 1.93
EBITDA 34.83
Effective Tax Rate (%) 25.06
Particulars MAR 2024 (Values in Cr)
Revenue 245.80
Operating Expense 225.84
Net Profit 15.92
Net Profit Margin (%) 6.47
Earnings Per Share (EPS) 1.88
EBITDA 35.14
Effective Tax Rate (%) 26.33
Particulars DEC 2023 (Values in Cr)
Revenue 161.48
Operating Expense 146.56
Net Profit 12.17
Net Profit Margin (%) 7.53
Earnings Per Share (EPS) 1.44
EBITDA 30.36
Effective Tax Rate (%) 25.83
Particulars MAR 2024 (Values in Cr)
Revenue 709.26
Operating Expense 647.39
Net Profit 49.42
Net Profit Margin (%) 6.96
Earnings Per Share (EPS) 5.84
EBITDA 121.30
Effective Tax Rate (%) 25.49
Particulars MAR 2023 (Values in Cr)
Revenue 522.05
Operating Expense 521.41
Net Profit 4.08
Net Profit Margin (%) 0.78
Earnings Per Share (EPS) 0.48
EBITDA 59.59
Effective Tax Rate (%) 26.48
Particulars MAR 2022 (Values in Cr)
Revenue 519.87
Operating Expense 456.42
Net Profit 68.04
Net Profit Margin (%) 13.08
Earnings Per Share (EPS) 8.04
EBITDA 119.68
Effective Tax Rate (%) 0.90
Particulars MAR 2021 (Values in Cr)
Revenue 563.18
Operating Expense 475.51
Net Profit 60.96
Net Profit Margin (%) 10.82
Earnings Per Share (EPS) 7.20
EBITDA 124.56
Effective Tax Rate (%) 33.09
Particulars MAR 2020 (Values in Cr)
Revenue 411.95
Operating Expense 366.29
Net Profit 32.69
Net Profit Margin (%) 7.93
Earnings Per Share (EPS) 3.86
EBITDA 85.03
Effective Tax Rate (%) 35.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 59.98
ROE % 9.87
ROCE % 11.69
Total Debt to Total Equity 0.54
EBITDA Margin 16.11
Particulars MAR 2023 (Values in Cr)
Book Value / Share 54.40
ROE % 0.83
ROCE % 3.77
Total Debt to Total Equity 0.56
EBITDA Margin 10.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 55.56
ROE % 15.41
ROCE % 12.50
Total Debt to Total Equity 0.59
EBITDA Margin 21.57
Particulars MAR 2021 (Values in Cr)
Book Value / Share 48.50
ROE % 16.07
ROCE % 17.43
Total Debt to Total Equity 0.54
EBITDA Margin 20.37
Particulars MAR 2020 (Values in Cr)
Book Value / Share 41.14
ROE % 9.76
ROCE % 12.95
Total Debt to Total Equity 0.45
EBITDA Margin 18.78
Particulars MAR 2024 (Values in Cr)
Book Value / Share 64.02
ROE % 9.28
ROCE % 11.22
Total Debt to Total Equity 0.50
EBITDA Margin 16.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 58.49
ROE % 0.83
ROCE % 3.65
Total Debt to Total Equity 0.52
EBITDA Margin 10.76
Particulars MAR 2022 (Values in Cr)
Book Value / Share 58.33
ROE % 14.76
ROCE % 12.17
Total Debt to Total Equity 0.56
EBITDA Margin 21.60
Particulars MAR 2021 (Values in Cr)
Book Value / Share 50.59
ROE % 15.32
ROCE % 16.90
Total Debt to Total Equity 0.52
EBITDA Margin 20.37
Particulars MAR 2020 (Values in Cr)
Book Value / Share 43.40
ROE % 9.24
ROCE % 12.47
Total Debt to Total Equity 0.43
EBITDA Margin 18.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 36.20
Total Assets 1034.09
Total Liabilities 1034.09
Total Equity 536.32
Share Outstanding 84652030
Price to Book Ratio 2.78
Return on Assets (%) 4.81
Return on Capital (%) 6.1
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.46
Total Assets 879.61
Total Liabilities 879.61
Total Equity 460.52
Share Outstanding 84652030
Price to Book Ratio 0.99
Return on Assets (%) -0.80
Return on Capital (%) -0.99
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 46.66
Total Assets 859.50
Total Liabilities 859.50
Total Equity 470.28
Share Outstanding 84652030
Price to Book Ratio 1.61
Return on Assets (%) 7.23
Return on Capital (%) 8.52
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.50
Total Assets 812.21
Total Liabilities 812.21
Total Equity 410.52
Share Outstanding 84652030
Price to Book Ratio 2.46
Return on Assets (%) 7.69
Return on Capital (%) 9.46
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 9.65
Total Assets 607.91
Total Liabilities 607.91
Total Equity 348.23
Share Outstanding 84652030
Price to Book Ratio 0.61
Return on Assets (%) 5.19
Return on Capital (%) 6.61
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 36.20
Total Assets 1068.25
Total Liabilities 1068.25
Total Equity 570.48
Share Outstanding 84652030
Price to Book Ratio 2.78
Return on Assets (%) 4.62
Return on Capital (%) 5.81
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 7.46
Total Assets 914.18
Total Liabilities 914.18
Total Equity 495.09
Share Outstanding 84652030
Price to Book Ratio 0.99
Return on Assets (%) 0.44
Return on Capital (%) 0.55
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 46.66
Total Assets 882.97
Total Liabilities 882.97
Total Equity 493.76
Share Outstanding 84652030
Price to Book Ratio 1.61
Return on Assets (%) 7.70
Return on Capital (%) 9.02
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.50
Total Assets 829.90
Total Liabilities 829.90
Total Equity 428.22
Share Outstanding 84652030
Price to Book Ratio 2.46
Return on Assets (%) 7.34
Return on Capital (%) 8.98
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 9.65
Total Assets 627.10
Total Liabilities 627.10
Total Equity 367.42
Share Outstanding 84652030
Price to Book Ratio 0.61
Return on Assets (%) 5.21
Return on Capital (%) 6.58
Particulars MAR 2024 (Values in Cr)
Net Income 66.10
Cash from Operations 65.52
Cash from Investing -52.07
Cash from Financing 30.67
Net change in Cash 28.73
Free Cash Flow 117.68
Particulars MAR 2023 (Values in Cr)
Net Income 5.34
Cash from Operations 27.05
Cash from Investing -29.75
Cash from Financing -31.96
Net change in Cash -39.27
Free Cash Flow 56.97
Particulars MAR 2022 (Values in Cr)
Net Income 68.49
Cash from Operations 59.98
Cash from Investing -27.15
Cash from Financing -11.74
Net change in Cash 6.15
Free Cash Flow 87.22
Particulars MAR 2021 (Values in Cr)
Net Income 91.11
Cash from Operations 106.49
Cash from Investing -151.59
Cash from Financing 92.01
Net change in Cash 30.87
Free Cash Flow 258.24
Particulars MAR 2020 (Values in Cr)
Net Income 50.75
Cash from Operations 51.81
Cash from Investing -42.56
Cash from Financing -2.40
Net change in Cash -5.25
Free Cash Flow 94.54
Particulars MAR 2024 (Values in Cr)
Net Income 66.33
Cash from Operations 65.52
Cash from Investing -52.07
Cash from Financing 30.67
Net change in Cash 28.73
Free Cash Flow 117.68
Particulars MAR 2023 (Values in Cr)
Net Income 5.54
Cash from Operations 27.05
Cash from Investing -29.75
Cash from Financing -31.96
Net change in Cash -39.27
Free Cash Flow 56.97
Particulars MAR 2022 (Values in Cr)
Net Income 68.65
Cash from Operations 59.98
Cash from Investing -27.15
Cash from Financing -11.74
Net change in Cash 6.15
Free Cash Flow 87.22
Particulars MAR 2021 (Values in Cr)
Net Income 91.11
Cash from Operations 106.49
Cash from Investing -151.59
Cash from Financing 92.01
Net change in Cash 30.87
Free Cash Flow 258.24
Particulars MAR 2020 (Values in Cr)
Net Income 50.75
Cash from Operations 51.81
Cash from Investing -42.56
Cash from Financing -2.40
Net change in Cash -5.25
Free Cash Flow 94.54
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

SMS PHARMACEUTICALS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
235.69 -1.89 redarrow
red-green-graph indicator
3 Bearish
13 Bullish
  • 5 Days 237.00
  • 26 Days 219.60
  • 10 Days 230.30
  • 50 Days 216.40
  • 12 Days 228.20
  • 100 Days 224.80
  • 20 Days 222.40
  • 200 Days 230.80
240.38 PIVOT

First Support

237.42

First Resistance

243.19

Second Support

234.61

Second Resistance

246.15

Third Support

231.65

Third Resistance

248.96

RSI

64.36

ADX

25.98

MACD

8.64

Williams % R

-13.94

Commodity Channel Index (CCI)

130.99

Date

2025-04-29

Week

124578.00

Same Day

40880.00

Month

75007.00

1 Year

1.16

3 Year

0.99

Over 1 Month

9.56%

down

Over 1 Year

15.69%

down

Over 3 Months

20.08%

down

Over 3 Years

34.31%

down

Over 6 Months

-16.21%

down

Over 5 Years

39.73%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SMS PHARMACEUTICALS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
31.22%
Promoter Holdings
66.26%
FII
0.08%
DII
2.43%
Promoter Shares(Pledge Percentage)
37.6%
Name Shares Category
Quant Mutual Fund - Quant Small Cap Fund 2153886.0 (2.43%) Public Shareholding
Venkata Subbaraju Penmatsa (huf) 1799900.0 (2.03%) Public Shareholding
Venkata Praveen Talluri 1320170.0 (1.49%) Public Shareholding
Sudeepthi Gopineedi 1320170.0 (1.49%) Public Shareholding
Vivek Mundra 1043628.0 (1.18%) Public Shareholding
Aniruddh Mundra 958540.0 (1.08%) Public Shareholding
Tvt Infracon Llp 100000.0 (0.0%) Shareholding of Promoter and Promoter Group
Potluri Infra Projects Llp 8846420.0 (0.0%) Shareholding of Promoter and Promoter Group
Potluri Laboratories Private Limited 1120320.0 (0.0%) Shareholding of Promoter and Promoter Group
Trilok Potluri 2188000.0 (0.0%) Shareholding of Promoter and Promoter Group
Vamsi Krishna Potluri 1.332837E7 (0.0%) Shareholding of Promoter and Promoter Group
Ramesh Babu Potluri 1.815306E7 (0.0%) Shareholding of Promoter and Promoter Group
Hima Bindu Potluri 1.500884E7 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SMS PHARMACEUTICALS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
22 Sep 2023 0.3 Final 22 Sep 2023 Equity shares
22 Sep 2022 0.3 Final 23 Sep 2022 Equity shares
22 Sep 2021 0.3 Final 24 Sep 2021 Equity shares
26 Mar 2020 0.25 Interim 28 Mar 2020 Equity shares
19 Sep 2019 0.25 Final 23 Sep 2019 Equity shares
11 Sep 2018 0.25 Final 13 Sep 2018 Equity shares
20 Sep 2017 0.2 Final 22 Sep 2017 Equity shares
22 Sep 2016 0.2 Final 24 Sep 2016 Equity shares
22 Sep 2015 2.0 Final 24 Sep 2015 Equity shares
23 Sep 2014 2.0 Final 25 Sep 2014 Equity shares
23 Sep 2013 2.0 Final 25 Sep 2013 Equity shares
22 Sep 2011 1.5 Final 24 Sep 2011 Equity shares
23 Sep 2010 1.0 Final 25 Sep 2010 Equity shares
23 Sep 2009 2.0 Final 25 Sep 2009 Equity shares
23 Dec 2008 2.0 Final 26 Dec 2008 Equity shares
21 Sep 2007 2.0 Final 25 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
17 Dec 2015 10.0 1.0 18 Dec 2015
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
22 Sep 2023 0.3 Final 22 Sep 2023 Equity shares
22 Sep 2022 0.3 Final 23 Sep 2022 Equity shares
22 Sep 2021 0.3 Final 24 Sep 2021 Equity shares
26 Mar 2020 0.25 Interim 28 Mar 2020 Equity shares
19 Sep 2019 0.25 Final 23 Sep 2019 Equity shares
11 Sep 2018 0.25 Final 13 Sep 2018 Equity shares
20 Sep 2017 0.2 Final 22 Sep 2017 Equity shares
22 Sep 2016 0.2 Final 24 Sep 2016 Equity shares
22 Sep 2015 2.0 Final 24 Sep 2015 Equity shares
23 Sep 2014 2.0 Final 25 Sep 2014 Equity shares
23 Sep 2013 2.0 Final 25 Sep 2013 Equity shares
22 Sep 2011 1.5 Final 24 Sep 2011 Equity shares
23 Sep 2010 1.0 Final 25 Sep 2010 Equity shares
23 Sep 2009 2.0 Final 25 Sep 2009 Equity shares
23 Dec 2008 2.0 Final 26 Dec 2008 Equity shares
21 Sep 2007 2.0 Final 25 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
17 Dec 2015 10.0 1.0 18 Dec 2015

SMS PHARMACEUTICALS LTD. Share Price

SMS Pharmaceuticals Limited was incorporated in December, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. Its business activity is a single primary business segment of 'Bulk Drugs'.

During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities.

During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24.

During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s. VKT Pharma Private Limited. With this the said company has become an associate company. The project of the said associate company is in final stage and at the verge of completion and operations are yet to be commenced. The Company has not having any subsidiaries.

During the year 2015-16, the Company had sub divided the face value of share of Rs 10/- each into face value of Rs 1/- of each with record date of 18th December 2015.

During FY 2015-16, the Board has approved the 'Draft Scheme of Arrangement for Demerger of Semi Regulated Units (Unit - I, IV & V) along with other Assets to transfer the same to SMS Lifesciences India Limited (Resulting Company), with an object to reduce the impact of Semi Regulated Units on Regulated Units, achieving operational efficiencies, site synergies and streamlining its current structure. The Draft Scheme of Arrangement is subject to the Approvals of Stock Exchanges, Securities Board of India Limited, Reserve Bank of India and other regulatory authorities and also Hon'ble High Court of Judicature at Hyderabad for the State of Telangana and Andhra Pradesh.

During FY 2016-17, the Company had made investment in it's associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2016-17, the Company had acquired 5,11,400 equity shares of face value of Rs 10/- each in the said associate at an average price of Rs 157.21. Further, the Company had also made an investment in 1000 equity shares of Sireen Drugs Private Limited of Rs 10/- each.

SMS Lifesciences India Limited is the wholly owned subsidiary of the Company during the Financial Year 2016-17.

The Semi Regulatory Units of the Company were demerged and transferred to SMS Lifesciences India Limited effective from 01-04-2016 and SMS LifeSciences India Limited was made a Wholly Owned Subsidiary of the Company in 2017. The said Scheme became effective from 17th May, 2017. In terms of the said Scheme, the Company allotted 30,23,287 equity shares of Rs.10/- each to the shareholders of the company on 23rd June, 2017.

The Company had made investment in its associate company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2017-18, the Company had acquired 7,84,100 equity shares of face value of Rs.10/- each in the said associate at an average price of Rs.200.81.

During FY 2018-19, the Company had made investment in it's associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. The Company held 38,50,165 equity shares of Rs 10/- each in VKT Pharma Private Limited as on 31st March 2019 as investments.

In 2020-21, the Company incorporated Joint Venture (JV) in Spain with nomenclature of 'CHEMO SMS ENTERPRISES SL' in the capital ratio of 55:45. The Ibuprofen product got launched in 2023.

Parent organization Indian Private
NSE symbol SMSPHARMA
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of SMS Pharmaceuticals Ltd?

Answer Field

The share price of SMS Pharmaceuticals Ltd for NSE is ₹ 235.69 and for BSE is ₹ 234.25.

What is the Market Cap of SMS Pharmaceuticals Ltd?

Answer Field

The market cap of SMS Pharmaceuticals Ltd for NSE is ₹ 19,95.16 Cr. and for BSE is ₹ 19,82.97 Cr. as of now.

What is the 52 Week High and Low of SMS Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of SMS Pharmaceuticals Ltd for NSE is ₹ 398.00 and ₹ 175.25 and for BSE is ₹ 398.00 and ₹ 175.00.

How to Buy SMS Pharmaceuticals Ltd share?

Answer Field

You can trade in SMS Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for SMS Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 15.69%.

What is the Current Share Price of SMS Pharmaceuticals Ltd?

Answer Field

SMS Pharmaceuticals Ltd share price is for NSE ₹ 235.69 & for BSE ₹ 234.25 as on Apr 30 2025 03:30 PM.

What is the Market Cap of SMS Pharmaceuticals Ltd Share?

Answer Field

The market cap of SMS Pharmaceuticals Ltd for NSE ₹ 19,95.16 & for BSE ₹ 19,82.97 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of SMS Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for SMS Pharmaceuticals Ltd share is 33.50.

What is the PB ratio of SMS Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for SMS Pharmaceuticals Ltd share is 73.15.

How to Buy SMS Pharmaceuticals Ltd Share?

Answer Field

You can trade in SMS Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy SMS Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy SMS Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “SMS Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|